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Abstract
There is paucity of literature about tolerability of standard chemoradiation in cervical cancer patients of rural
background; hence, we undertook this study. Enteritis and dyselectrolytemias were the most common tox-
icities and the key reasons for radiation interruption and suboptimal chemotherapy doses. Nutritional and
social support along with vigorous assessment for dyselectrolytemias and timely management is the key to
optimizing treatment.
Background: Concurrent chemoradiation causes toxicities such as enteritis, hematologic toxicities which may lead to
treatment interruptions, and therefore inferior outcomes. Adequate supportive care is very important to complete the
scheduled protocol. Most of our patients are from rural background with a heterogeneous social background (nutrition
and social support). There is paucity of literature to evaluate the tolerance of this intense treatment in these groups of
patients, and hence, this study was undertaken.Methods: In this observational study, 30 rural women having carcinoma
cervix treated with concurrent chemoradiation between January and July 2013 were reviewed retrospectively. They were
assessed weekly for dyselectrolytemia, enteritis, and hematologic toxicity using Radiation Therapy Oncology Group
Acute Radiation Morbidity Scoring Criteria. Treatment gaps along with reasons were recorded and correlated. Results:
Median age of patients was 54 years. Of the patients, 43.3%were International Federation of Gynecology and Obstetrics
stage II and 46.7% stage III. Grade 3 enteritis was seen in 7 of 30 patients (23.3%). None (0%) had grade 3 or higher
hematologic toxicity. Dyselectrolytemiaehyponatremia (46.66%), hypokalemia (26.66%), hypocalcemia (6.66%), and
hypomagnesemia (10%) were noted. Two of thirty patients (6.66%) received the planned 5 cycles, cisplatin 40 mg/m2
weekly. There were treatment interruptions in radiation in 6 (20%) and treatment delays in chemotherapy in 10 (33.33%)
patients. Conclusion: Concurrent chemoradiation for patients from rural areas is associated with higher acute toxicities.
Regular monitoring for enteritis and dyselectrolytemias and timely intervention can help improve compliance and
decrease treatment interruptions and thereby achieve the optimum treatment outcome.
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Cervical carcinoma is one of leading malignancies in Indian
women with a higher burden as compared to western countries. In
India, it accounts for 16% of all cancers in urban women and 37%
of the cancers in rural women as published in 2009.1 After National
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http://dx.doi.org/10.1016/j.cogc.2014.12.003chemoradiation using cisplatin as it has shown to reduce the risk
of death by 30% to 50%.2 Radiation therapy is delivered via tele-
therapy to a dose of 45 to 50 Gy followed by brachytherapy to a
cumulative dose of 75 to 80 Gy to point A. This is combined with
weekly 40 mg/m2 cisplatin chemotherapy for 5 cycles.
Patients receiving chemoradiation have increased treatment-
related toxicities as compared to radiation alone. These most
commonly are nausea, enteritis, and hematologic toxicities. The
odds ratios for grade 3 to 4 hematologic toxicities and grade 3 to 4
gastrointestinal (GI) toxicities in those who receive chemoradiation
as against those treated with radiation alone are 8.97 and 2.77,
respectively.3 These toxicities cause treatment interruptions in-
creasing overall treatment time and cumulative dose reduction of
cisplatin. It compromises local control as prolongation of treat-
ment beyond 56 days causes the local control to fall by 1% per
day.4Clinical Ovarian and Other Gynecologic Cancer December 2014 - 29
Table 1 Showing Stage-Wise Distribution of Patients
Stage (FIGO) Number of Patients (%)
Stage I 2 (6.66)
Stage II 13 (43.33)
Stage III 14 (46.66)
Stage IVA 1 (3.33)
Concurrent Chemoradiation in Rural Cervical Cancer
30 -Adequate nutritional and supportive care is needed to manage
side effects. These supportive parameters differ in different popu-
lation backgrounds. Ours being a tertiary care set up with academic
program, many patients from rural areas with compromised nutri-
tional status receive treatment in our hospital. Of the patients with
cervical cancer treated in our hospital between 1998 and 2005,
54.7% (140 of 257) were from rural background.5 This study is
attempted to assess the treatment compliance, enteritis, and he-
matologic toxicities in women of rural background treated with
concurrent chemoradiation for cervical carcinoma. Rural back-
ground was particularly chosen as it constitutes over 60% of the
Indian population, and the prevalence of cervical carcinoma is high
in them. There is paucity of data regarding tolerance of standard
chemoradiation in patients of rural background. Additional data will
facilitate tailoring the treatment in the population.
Material and Methods
Patients
This is a retrospective study. Thirty patients of biopsy-proven
cervical carcinoma (International Federation of Gynecologists and
Oncologists [FIGO] stage IB to IVA) from rural background received
treatment in our hospital between January and July 2013, and they
were the subjects of our study. Their case ﬁles were reviewed. De-
mographic details were noted, and the diagnosis and stage were
recorded according to the FIGO staging system.6 Postoperative and
palliative cases were excluded. Also, those patients with a history of
inﬂammatory bowel disease or those who have medical comorbidities
which deem them unﬁt for chemotherapy were excluded.
Treatment
All patients were treated with radical intent, and none of them
had received any prior oncology directed treatment. After obtaining
written informed consent, external beam radiotherapy (EBRT) was
delivered to a dose of 4500 cGy in 25 fractions using a 6-MV linear
accelerator with SSD at 100 cm using 3-dimensional conformal
radiation therapy. The volumes of interest were as per standard
guidelines.7 Cisplatin was planned to a dose of 40 mg/m2
concurrently with EBRT for 5 cycles. All patients were treated
as inpatients during concurrent chemoradiation. Minimum of
10 gm/dL hemoglobin was maintained at the beginning of treat-
ment. After a gap of 2 weeks, intracavitary brachytherapy was done
under combined spinal/epidural anesthesia using manual after-
loading low-dose-rate cesium sources. The planning was done by
digitizing the sources on orthogonal x-rays and a dose of 30 Gy was
prescribed to point A.
Toxicity Assessment During EBRT
Weekly blood counts (complete hemogram), renal function tests,
and serum electrolytes were measured. The number of episodes of
loose stools and vomiting was documented. Abnormalities in blood
parameters and degree of enteritis were graded as per Radiation
Therapy Oncology Group (RTOG) Acute Radiation Morbidity
Scoring Criteria8 (described in the following) and accordingly
treated. Implications of these toxicities in terms of treatment in-
terruptions were recorded and correlated.
RTOG Acute Radiation Morbidity Scoring Criteria.
Abbreviation: FIGO ¼ Féderation Internationale de Gynécologie et d’Obstétrique.
ClinicalGrade 0: indicates no change in bowel habit.Ovarian and Other Gynecologic Cancer December 2014Grade 1: increased frequency or change in quality of bowel
habits not requiring medication or rectal discomfort not
requiring analgesics.
Grade 2: diarrhea requiring parasympatholytic drugs (eg,
Lomotil)/mucous discharge not necessitating sanitary pads/
rectal or abdominal pain requiring analgesics.
Grade 3: diarrhea requiring parenteral support/severe mu-
cous or blood discharge necessitating sanitary pads/abdom-
inal distention. (Flat-plate radiograph demonstrates
distended bowel loops.)
Grade 4: acute or subacute obstruction, ﬁstula, or perfora-
tion; GI bleeding requiring transfusion; abdominal pain or
tenesmus requiring tube decompression or bowel diversion.Results
Total patients reviewed were 30. The Karnofsky performance
score for all patients ranged from 80 to 90.
Study Population
Patients’ age ranged from 30 to 75 years with a mean of 52.53
years and median of 54 years. Thirteen patients (43.33%) were  50
years and 17 (56.66%) were > 50 years. Most patients belonged to
FIGO stages II and III. The stage-wise distribution of the patients is
presented in Table 1. All patients had squamous cell carcinoma.
Toxicities
Patients were assessed for acute toxicities encountered during
radiation therapy. Weekly scoring of radiation enteritis as per
RTOG scoring criteria revealed maximum enteritis scores for each
patient as presented in Table 2. Of the patients, 76.66% had grade I
to II toxicities, whereas 23.33% had grade III toxicities.
The changes encountered in parameters of hemogram per-
taining to hemoglobin, total leukocyte count, and absolute
neutrophil count are provided in Table 3. There was no signiﬁ-
cant drop in platelet count in any of the subjects of our study.
Serum creatinine also remained normal throughout the study for
all patients. Figure 1 shows a graph of percentage of patients who
had dyselectrolytemia during the treatment course. Decrease in
serum sodium was the most frequent abnormality (14 of 30)
followed by potassium (8 of 30).
Treatment Gaps During Radiation Therapy
Six patients (20%) required gap during radiation therapy. The
gap ranged from 3 to 10 days. The reasons were 3 patients had grade
3 enteritis, 1 had dyselectrolytemia, 1 had severe pain abdomen, and
1 had both grade 3 enteritis and dyselectrolytemia.
Figure 1 Graph Showing Percentage of Patients Who Had
Dyselectrolytemias. X-Axis, Percentage of Patients
With Dyselectrolytemia. Y-Axis, Electrolytes
Measured. Hyponatremia Was the Most Common
Abnormality (14 of 30 Patients). Eight, Two, and
Three Patients Had Hypokalemia, Hypocalcemia, and
Hypomagnesemia, Respectively. Most Were Managed
With Oral Supplements, Whereas 3.3% to 6.7%
Required Intravenous (IV) Correction
Table 4 Number of Chemotherapy Cycles Received and the
Reasons for Interruption in Chemotherapy
Number of Cycles Received Number of Patients (%)
Table 2 Patients Who Suffered Enteritis
Gradea (RTOG) Number of Patients (%)
Grade 1 11 (36.66)
Grade 2 12 (40)
Grade 3 7 (23.33)
Grade 4 0 (0)
Abbreviation: RTOG ¼ Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring
Criteria.
aWorst enteritis grade during treatment.
Ritika R. Harjani et alChemotherapy Cycles
Cycles of cisplatin (40 mg/m2) received ranged from 2 to 5.
Twenty-two patients (73.33%) received 4 cycles. Two of thirty
patients received the planned 5 cycles. The distribution of the
number of cycles received by the patients is given in Table 4. Cu-
mulative cisplatin dose ranged from 80 to 200 mg/m2 with a mean
of 152 mg/m2 and median dose of 160 mg/m2. The patients having
delays in subsequent chemotherapy cycles were 10 (33.33%). The
reasons for the interruptions in chemotherapy cycles are given in
Table 4.
Discussion
Cervical carcinoma in rural areas has outnumbered the incidence
in urban registries and hence is an important health concern. The
most important acute adverse events are hematologic toxicities and
enteritis. Acute effects start from the second week onward and peak
by the fourth to ﬁfth week.9
There are only few articles where feasibility of either radiation
alone or chemoradiation is well studied in rural population. In a
study by Jain et al.,10 on outcome of patients treated with radical
radiotherapy alone in cervical carcinoma in a rural center in India,
they did not come across any signiﬁcant acute toxicities. These re-
sults can be attributed to absence of chemotherapy in their treat-
ment regimen. In the study, they have highlighted the problems in
rural areas being poor ﬁnancial status, illiteracy, and ignorance
about disease.
In our study, 76.6% women had grade 1 to 2 enteritis, whereas 7
patients (23.3%) had grade 3 enteritis and none (0%) had grade 4
enteritis. This is greater than an Indian study by Saibishkumar
et al.11 in which grade 3 and higher GI toxicities was seen in 7 of
57 (12.3%) patients receiving concurrent chemoradiation. This can
be explained as the upper ﬁeld border for treatment portals was kept
at L5-S1 in their study as against aortic bifurcation7 in our study.
Also, chemotherapy dose used was less (35 mg/m2) and neverTable 3 Percentage of Patients Having RTOG Grade 2 and








Grade 3 or 4
Toxicities (%)
Hemoglobin 6 (20) 0 (0)
Total leukocyte count 5 (16.66) 0 (0)
Absolute neutrophil count 1 (3.33) 0 (0)
Abbreviation: RTOG ¼ Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring
Criteria.exceeded 50 mg/cycle. Our patients received doses of 40 mg/m2 and
doses reached up to 70 mg/cycle. Also, all our patients were from
rural background, whereas the above study constituted a mixed
population. Compromised pretreatment nutritional status could
have impacted and led to higher toxicities.
In the same study, 7% had grade 3 or 4 hematologic toxicities,11
whereas our study showed 0% grade 3 or 4 hematologic toxicities.
The probable reasons are that we treated our patients as inpatients
and intervened earlier. In the quoted study, the same was done
when grade 3 hematologic toxicity developed.
A study by Mukund et al.12 reported electrolyte disturbances
during concurrent chemoradiation using cisplatin in patients with
squamous cell carcinoma of esophagus, cervix, and head and neck.
Disturbances such as hypomagnesemia (60%), hypocalcemia
(89%), and hypokalemia (95%) were observed after 5 cycles of
cisplatin-based chemotherapy. Our study results—hyponatremia
(46.66%), hypokalemia (26.66%), hypocalcemia (6.66%), and2 Cycles 2 (6.66)
3 Cycles 4 (13.33)
4 Cycles 22 (73.33)
5 Cycles 2 (6.66)





One patient had both intractable vomiting (misc) and dyselectrolytemia.
One patient had both hematologic toxicity and dyselectrolytemia.
aMiscellaneous includes severe pain in abdomen and intractable nausea (1 patient each).
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32 -hypomagnesemia (10%)—were better. However, it is important to
note that they assessed only those patients who received full planned
chemotherapy of 5 cycles and also they had not conﬁned their study
to cervical cancer patients alone, and therefore, a direct comparison
cannot be made with the present study.
The toxicities led to treatment gaps. In our study, 20% women
had treatment gaps (range, 3-10 days). A prospective randomized
study by Singh et al.13 conducted in cervical cancer (stages IIB to
IIIB) found treatment delays in 16.3% patients treated with
concurrent chemoradiation correlating with the percentage of gaps
in our study. In Saibishkumar et al.,11 overall 28% patients in
chemoradiotherapy protocol had breaks in radiation therapy
schedule. We can ascribe better compliance in our study to daily
assessment of patients and timely management of toxicities as all
our patients were treated on an inpatient basis. Also, dyselec-
trolytemia assessment and prompt correction was also undertaken
in our study.
Cisplatin is a known nephrotoxic drug. Renal insufﬁciency
manifests as increase in creatinine and decrease in serum electro-
lytes, especially sodium, potassium, and magnesium. These effects
are dose dependent, with few happening below 20 mg/m2. Also,
radiation-induced enteritis causes loss of water and salts from the
body aggravating electrolyte imbalance. Repeated electrolyte
monitoring is thus important and recommended.14 Although these
effects are mentioned in literature, there has not been any
emphasis on regular monitoring and its implication on treatment
compliance. To the best of our knowledge, ours is the ﬁrst study to
document electrolyte changes so aggressively. We want to high-
light its importance that if adequately managed, treatment in-
terruptions can be decreased, which could otherwise compromise
disease control.
Our patients received cumulative cisplatin dose ranging from 80 to
200 mg/m2 over 2 to 5 cycles. Compliance of our patients was poor
for planned cycles, which was similar to that by Saibishkumar et al.11
Trials showing beneﬁt are the ones where a cumulative dose of
cisplatin used ranged from 225 to 240 mg/m2.15-17 This dose was
not achieved in our study and in the study by Saibishkumar et al.11
This could lead to compromise in local control. Chemotherapy
toxicities lead to treatment gaps, and it is known that beyond 7 to 8
weeks, delay of 1 day causes the local control to fall by 1%.4
The strength of our study is that all patients of the study were
treated on inpatient basis, and hence, daily rounds, assessment, and
management were timely and optimum. Also, we suggest that
pretreatment nutritional evaluation can be tried to ensure better
compliance. The limitation is that we have not compared with
women from urban areas. Second, it is a retrospective study and is of
small sample size.
Conclusion
Concurrent chemoradiation for cervical cancer patients from
rural areas is associated with higher acute toxicities. Regular moni-
toring for enteritis and dyselectrolytemia and appropriate timely
intervention can help improve compliance and decrease treatment
interruptions and thereby achieve the optimum treatment outcome.Clinical Ovarian and Other Gynecologic Cancer December 2014Clinical Practice Points
 Concurrent chemoradiation is the standard of care in cervical
cancer. It causes toxicities such as anemia, neutropenia, enteritis,
and renal insufﬁciency. Patients from rural background have less
awareness of importance of treatment time and less nutritional
and psychosocial support to withstand this aggressive treatment.
 Dyselectrolytemias and dehydration are found to be a signiﬁcant
toxicity in many of these patients, which hinders their tolera-
bility. Most common electrolyte imbalances are hyponatremia,
hypokalemia, hypocalcemia, and hypomagnesemia. They lead to
treatment interruptions (increasing overall treatment time) and
suboptimal chemotherapy doses compromising cure.
 Nutritional and psychosocial support along with timely assess-
ment and prompt intervention of electrolyte imbalance, regular
assessment of enteritis, and dehydration can help achieve the
optimal treatment in these patients.Disclosure
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